The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $84.34

Today's change-2.41 -2.78%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $84.34

Today's change-2.41 -2.78%
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc crosses below 50-day moving average

Vertex Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$2.41 or 2.78% to (U.S.)$84.34 and crossing below its 50-day moving average. Over the last five days, shares have lost 2.83% and are down 32.97% for the last year to date. This security has underperformed the S&P 500 by 29.88% during the last year.

Key company metrics

  • Open(U.S.) $85.90
  • Previous close(U.S.) $86.75
  • High(U.S.) $86.23
  • Low(U.S.) $83.40
  • Bid / Ask(U.S.) $83.80 / (U.S.) $88.30
  • YTD % change-32.97%
  • Volume2,887,997
  • Average volume (10-day)2,405,824
  • Average volume (1-month)2,336,740
  • Average volume (3-month)2,452,780
  • 52-week range(U.S.) $75.90 to (U.S.) $143.45
  • Beta0.54
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward68.79×
  • Forward PEG1.26×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.65
Updated April 29 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue418310166139
Total other revenue--------
Total revenue418310166139
Gross profit356280151129
Total cost of revenue6230159
Total operating expense472380337310
Selling / general / administrative971009486
Research & development310246224216
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)222-3
Other operating expenses, total1213
Operating income-54-70-171-172
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-76-92-191-198
Income after tax-75-94-221-199
Income tax, total-11300
Net income-74-95-189-199
Total adjustments to net income--------
Net income before extra. items-74-95-189-199
Minority interest1-1320
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-74-95-189-199
Inc. avail. to common incl. extra. items-74-95-189-199
Diluted net income-74-95-189-199
Dilution adjustment--------
Diluted weighted average shares243242241239
Diluted EPS excluding extraordinary itemsvalue per share-0.30-0.39-0.78-0.83
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.30-0.39-0.78-0.84